Home > Rheumatology > Experimental lupus therapy only shows significant effect at highest dose

Experimental lupus therapy only shows significant effect at highest dose


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
The New England Journal of Medicine
Reuters Health - 16/03/2022 - Up to 54% of patients with systemic lupus erythematosus (SLE) were helped by daily therapy with Bristol Myers Squibb's experimental drug iberdomide, but only at the highest dose tested, researchers report in Thursday's New England Journal of Medicine. The phase 2 study of 288 volunteers rated benefit based on a 105-point scale that assessed lupus activity. A 4-point drop during the 24-week treatment period was considered improvement. That was achieved by 54% of the 81 patients given a 0.45 mg dose, 40% of the 82 who received 0.30 mg daily, 48% of 42 treated with 0.15 mg, and 35% of the 83 given placebo. Only the difference between placebo and the highest dose was significant (P=0.01). The new results are "potentially exciting," Dr. Karen Costenbader of Brigham and Women's Hospital in Boston writes in an accompanying editorial. But, she cautions that "there have been too many phase 3 trial failures" for potential SLE treatm...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on